IDEAYA Biosciences (IDYA) Competitors $25.38 -0.23 (-0.90%) (As of 12/23/2024 05:26 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IDYA vs. ROIV, ASND, RVMD, LNTH, LEGN, NUVL, ELAN, CYTK, BPMC, and BBIOShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Elanco Animal Health Cytokinetics Blueprint Medicines BridgeBio Pharma IDEAYA Biosciences (NASDAQ:IDYA) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is IDYA or ROIV more profitable? Roivant Sciences has a net margin of 3,827.42% compared to IDEAYA Biosciences' net margin of 0.00%. Roivant Sciences' return on equity of -14.65% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -19.42% -18.63% Roivant Sciences 3,827.42%-14.65%-13.19% Does the MarketBeat Community prefer IDYA or ROIV? IDEAYA Biosciences received 88 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 71.28% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes13971.28% Underperform Votes5628.72% Roivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% Which has preferable earnings and valuation, IDYA or ROIV? Roivant Sciences has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$3.92M559.32-$112.96M-$2.33-10.89Roivant Sciences$124.79M69.83$4.35B$5.652.12 Which has more volatility & risk, IDYA or ROIV? IDEAYA Biosciences has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Does the media refer more to IDYA or ROIV? In the previous week, IDEAYA Biosciences had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for IDEAYA Biosciences and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat IDEAYA Biosciences' score of 0.60 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of IDYA or ROIV? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate IDYA or ROIV? IDEAYA Biosciences presently has a consensus price target of $53.67, suggesting a potential upside of 111.45%. Roivant Sciences has a consensus price target of $17.93, suggesting a potential upside of 49.78%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe IDEAYA Biosciences is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 SummaryRoivant Sciences beats IDEAYA Biosciences on 11 of the 19 factors compared between the two stocks. Ad InvestorPlaceSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just months ago. Louis has identified six specific AI stocks that are poised to benefit from this.Click here to learn which AI companies Louis believes will dominate the market... Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.19B$6.69B$5.20B$9.15BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-10.8910.5287.1917.11Price / Sales559.32193.661,163.55122.70Price / CashN/A57.1643.2337.84Price / Book2.635.134.804.78Net Income-$112.96M$151.58M$120.46M$225.43M7 Day Performance-3.61%-1.40%-0.89%-0.78%1 Month Performance-5.26%-3.69%14.87%1.05%1 Year Performance-26.77%9.07%29.57%15.79% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.3497 of 5 stars$25.38-0.9%$53.67+111.5%-26.8%$2.19B$3.92M-10.8980ROIVRoivant Sciences2.8739 of 5 stars$11.88+2.7%$17.93+50.9%+9.9%$8.65B$124.79M2.10860ASNDAscendis Pharma A/S3.1315 of 5 stars$138.00+1.2%$191.77+39.0%+12.2%$8.37B$327.43M-17.08640RVMDRevolution Medicines4.4655 of 5 stars$44.02-0.1%$65.82+49.5%+61.0%$7.41B$742,000.00-12.26443LNTHLantheus4.3114 of 5 stars$90.72+1.6%$131.86+45.3%+52.7%$6.31B$1.50B15.09834Positive NewsLEGNLegend Biotech1.4246 of 5 stars$33.62-1.3%$81.54+142.5%-43.3%$6.14B$520.18M-35.391,800NUVLNuvalent2.2134 of 5 stars$84.39+0.2%$112.60+33.4%+14.7%$6.00BN/A-24.3240Positive NewsELANElanco Animal Health3.6694 of 5 stars$11.75+1.0%$16.71+42.2%-19.2%$5.81B$4.45B29.389,300CYTKCytokinetics3.9458 of 5 stars$49.01+0.3%$84.07+71.5%+9.8%$5.78B$3.22M-9.11250BPMCBlueprint Medicines2.5631 of 5 stars$89.17-1.1%$123.33+38.3%+1.7%$5.66B$434.42M-42.26640BBIOBridgeBio Pharma4.5755 of 5 stars$27.58+4.1%$47.69+72.9%-32.4%$5.21B$217.77M-11.44400Analyst Forecast Related Companies and Tools Related Companies Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Legend Biotech Alternatives Nuvalent Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDYA) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts